Daniel E. Lopes de Menezes

Author

University of Alberta

Also Known As

D. E. Lopes de Menezes, D.E.Lopes de Menezes, Daniel E. Lopes de Menezes, Daniel E.Lopes de Menezes

Publications

894

Citations

H-Index

Concepts

All Affiliations

University of Alberta Novartis (United States)University of British Columbia

About

Daniel E. Lopes de Menezes is an author at University of Alberta specializing in immunotherapy, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	284
2	Immunology	5	5	284
3	Pharmacology	3	3	428
4	Cell Biology	2	2	99
5	Pathology	1	1	28

Daniel E. Lopes de Menezes

Publications

889

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics of long-circulating liposomes Theresa M. Allen, Christian Hansen, Daniel E. Lopes de Menezes Advanced Drug Delivery Reviews Lipid PreparationLong-circulating LiposomesLipid MovementPharmacologyExosomes	1995	300
CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i> Archie Tse, Katherine G. Rendahl, Tahir Sheikh, Clinical Cancer Research	2007	149
CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia Daniel E. Lopes de Menezes, Jing Peng, Evelyn N. Garrett, Clinical Cancer Research	2005	111
Long-circulating, polyethylene glycol-grafted immunoliposomes Samuel Zalipsky, Christian Hansen, Daniel E. Lopes de Menezes, Journal of Controlled Release Cell-based Drug DeliveryPolyethylene Glycol-grafted ImmunoliposomesImmunologyImmunotherapyMedicine	1996	73
Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells Daniel E. Lopes de Menezes, Marc Kirchmeier, Jean-François Gagné, Journal of Liposome Research ImmunologyImmunotherapyTumor BiologyPolyethylene GlycolCell Surface	1999	71
Immunoliposome-mediated targeting of anti-cancer drugs <i>in vivo</i> Theresa M. Allen, Israr Ahmad, Daniel E. Lopes de Menezes, Biochemical Society Transactions Molecular PharmacologyDrug TargetingImmunoliposome-mediated TargetingMedicineNovember 1995	1995	57
Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo Daniel E. Lopes de Menezes, Linda M. Pilarski, Andrew R. Belch, Biochimica et Biophysica Acta (BBA) - Biomembranes Drug TargetingMedicineMalignant Blood DisorderImmunologySelective Targeting	2000	55
Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma Daniel E. Lopes de Menezes, Kimberly Denis-Mize, Yan Tang, Journal of Immunotherapy Rituximab Single AgentsLymphoid NeoplasiaRituximab FCancer ImmunosurveillanceMedicine	2006	28
Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: Correlation with Western blot analysis Wieslawa H. Dragowska, Daniel E. Lopes de Menezes, Jason Sartor, Cytometry	2000	23
Combined treatment of Bcl‐2 antisense oligodeoxynucleotides (G3139), p‐glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug‐resistant growth of drug‐resistant breast cancer in severely combined immunodeficient mice Daniel E. Lopes de Menezes, Yanping Hu, Lawrence D. Mayer Journal of Experimental Therapeutics and Oncology	2003	22

Page 1